摘要
冠状动脉粥样硬化性心脏病(coronary atherosclerotic heart disease,CHD)简称冠心病,是全世界发生率较高的心血管疾病,经皮冠状动脉介入(percutaneous coronary intervention,PCI)是现阶段CHD治疗的有效方法,但支架内再狭窄(in-stent restenosis,ISR)影响着患者预后,增加不良心血管事件发生风险。随着裸金属支架(bare-metal stent,BMS)的应用,ISR患者的治疗进入一个新阶段,之后药物涂层支架(drug eluting stents,DES)、药物涂层球囊(drug-coated balloon,DCB)、斑块消融技术及可降解材料逐渐应用,为疾病治疗提供更多的选择,更有利于提高治疗效果。基于此,本文通过对ISR概念、发生机制、治疗进展进行综述。
Coronary atherosclerotic heart disease(CHD),referred to as coronary heart disease for short,is a cardiovascular disease with a high incidence in the world,percutaneous coronary intervention(PCI)is an effective treatment for CHD at present,but in-stent restenosis(ISR)affects the prognosis of patients and increases the risk of cardiovascular events.With the application of bare-metal stent(BMS),the treatment of ISR patients has entered a new stage,after that,drug-coated stents(DES),drug-coated balloon(DCB),plaque ablation technology and degradable materials are gradually applied,which provides more choices for disease treatment,and it is more conducive to improving the treatment effect.Based on this,this article provided a review of the concept,pathogenesis and treatment progress of ISR.
作者
余一平
YU Yiping(Medical College of Shaoxing Wenli University,Shaoxing 312000,China)
出处
《中外医学研究》
2024年第14期181-184,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
冠状动脉粥样硬化性心脏病
经皮冠状动脉介入
支架内再狭窄
治疗进展
Coronary atherosclerotic heart disease
Percutaneous coronary intervention
In-stent restenosis
Treatment progress
